Polymorphisms of the promoter and exon 3 of the receptor for advanced glycation end products (<i>RAGE</i>) in Euro‐ and Afro‐Brazilians

Torres, Mayara; Beltrame, Márcia Holsbach; Santos, Izabella C.R. dos; Picheth, Geraldo; Petzl-Erler, María Luiza; Pedrosa, Fábio O.; Steffens, Maria; Souza, Emanuel M.

doi:10.1111/j.1744-313x.2011.01073.x

Cited by 10 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[9,13,14] More than 50 polymorphisms have been identified in the region of the RAGE gene. [15] Of these, the RAGE Gly82Ser polymorphism (rs2070600), representing a glycine (G) to serine (S) substitution, is of interest because of its localization in the N-linked glycation site (position 82), which could influence AGE–RAGE interaction. [16] Some studies in humans and animals have yielded conflicting results concerning the potential role of the RAGE Gly82Ser polymorphism in the pathogenesis of atherosclerosis.…”

Section: Introductionmentioning

confidence: 99%

Association of RAGE gene Gly82Ser polymorphism with coronary artery disease and ischemic stroke

Ma¹,

Qu²,

Zhao

et al. 2016

Medicine

View full text Add to dashboard Cite

Background:The receptor for advanced glycosylation end products (RAGE) has been widely linked to diabetic atherosclerosis, but its effects on coronary artery disease (CAD) and ischemic stroke (IS) remain controversial. The Gly82Ser polymorphism is located in the ligand-binding V domain of RAGE, suggesting a possible influence of this variant on RAGE function. The aim of the present study is to clarify the association between the RAGE Gly82Ser polymorphism and susceptibility to CAD and IS.Methods:Eligible studies were identified through a comprehensive literature search. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the association of Gly82Ser polymorphism with CAD and IS risk. Fixed- or random-effects model was used depending on the heterogeneity between studies. A funnel plot and Egger linear regression test were applied to assess publication bias. We also performed subgroup analyses to investigate potential sources of heterogeneity.Results:A total of 16 eligible articles containing 18 studies were analyzed. The pooled analysis indicated that the Gly82Ser polymorphism significantly increased CAD risk in recessive and homozygous genetic models (SS vs GS + GG: OR = 1.34, 95% CI = 1.09–1.64; SS vs GG: OR = 1.38, 95% CI = 1.12–1.71). A significant association between the Gly82Ser polymorphism and IS risk was observed in all tested models except the heterozygous genetic model (GS + SS vs GG: OR = 1.20, 95% CI = 1.04–1.38; SS vs GS + GG: OR = 2.20, 95% CI = 1.74–2.78; SS vs GG: OR = 2.23, 95% CI = 1.72–2.91; S vs G: OR = 1.32, 95% CI = 1.05–1.65). Subgroup analysis suggested an association between CAD and IS risk and the Gly82Ser polymorphism in the Chinese population, but not in the non-Chinese population.Conclusions:The current meta-analysis suggests that the RAGE Gly82Ser polymorphism is associated with an increased risk of CAD and IS, especially in the Chinese population. However, better-designed studies with larger sample sizes are needed to validate the results.

show abstract

Section: Introductionmentioning

confidence: 99%

Association of RAGE gene Gly82Ser polymorphism with coronary artery disease and ischemic stroke

Ma¹,

Qu²,

Zhao

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…Moreover, it cannot be totally ruled out that the evolutionary history of linkage disequilibrium patterns will vary significantly in different ethnic populations. For example, the degrees of linkage disequilibrium between rs1800625 and rs1800624 were differentiated between Euro- and Afro-Brazilians [16] and Han Chinese in this study. Further in this study all examined polymorphisms respected the Hardy-Weinberg equilibrium in both patients and controls, lowering the likelihood of being biased by faulty genotyping or population stratification.…”

Section: Discussionmentioning

confidence: 53%

“…No significance was reached for the other two polymorphisms under study. Moreover, considering the absolute linkage disequilibrium between rs1800625 and rs1800624 reported in Euro- and Afro-Brazilians [16], the relation of these two polymorphisms was checked in all individuals, and the linkage disequilibrium was only moderate (D' = 0.67), indicating the potential existence of genetic heterogeneity across ethnicities.…”

Section: Resultsmentioning

confidence: 99%

An Interactive Association of Advanced Glycation End-Product Receptor Gene Four Common Polymorphisms with Coronary Artery Disease in Northeastern Han Chinese

Zhu

Xia

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

BackgroundGrowing evidence indicates that advanced glycation end-product receptor (RAGE) might play a contributory role in the pathogenesis of coronary artery disease (CAD). To shed some light from a genetic perspective, we sought to investigate the interactive association of RAGE gene four common polymorphisms (rs1800625 or T-429C, rs1800624 or T-374A, rs2070600 or Gly82Ser, and rs184003 or G1704A) with the risk of developing CAD in a large northeastern Han Chinese population.Methodology/Principal FindingsThis was a hospital-based case-control study incorporating 1142 patients diagnosed with CAD and 1106 age- and gender-matched controls. All individuals were angiographically confirmed. Risk estimates were expressed as odds ratio (OR) and 95% confidence interval (CI). Overall there were significant differences in the genotype and allele distributions of rs1800625 and rs184003, even after the Bonferroni correction. Logistic regression analyses indicated that rs1800625 and rs184003 were associated with significant risk of CAD under both additive (OR = 1.20 and 1.23; 95% CI: 1.06–1.37 and 1.06–1.42; P = 0.006 and 0.008) and recessive (OR = 1.75 and 2.39; 95% CI: 1.28–2.40 and 1.47–3.87; P<0.001 and <0.001) models after adjusting for confounders. In haplotype analyses, haplotypes C-T-G-G and T-A-G-T (alleles in order of rs1800625, rs1800624, rs2070600 and rs184003), overrepresented in patients, were associated with 52% (95% CI: 1.19–1.87; P = 0.0052) and 63% (95% CI: 1.14–2.34; P = 0.0075) significant increases in adjusted risk for CAD. Further interactive analyses identified an overall best multifactor dimensionality reduction (MDR) model including rs1800625 and rs184003. This model had a maximal testing accuracy of 0.6856 and a cross-validation consistency of 10 out of 10 (P = 0.0016). The validity of this model was substantiated by classical Logistic regression analysis.ConclusionsOur findings provided strong evidence for the potentially contributory roles of RAGE multiple genetic polymorphisms, especially in the context of locus-to-locus interaction, in the pathogenesis of CAD among northeastern Han Chinese.

show abstract

“…RAGE–ligand interaction and their interaction with other molecules play an important role in the pathogenesis of cancer progression and metastasis. [ 6 , 11 ]…”

Section: Introductionmentioning

confidence: 99%

Receptor for advanced glycation end-product rs1800624 polymorphism contributes to increase breast cancer risk

Zhang¹,

Deng²,

Tang

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Although several studies have identified an association between the receptor for advanced glycation end-product (RAGE) rs1800624 polymorphism and breast cancer, the results have been conflicting. Therefore, we conducted a meta-analysis to assess the relationship between the RAGE rs1800624 polymorphism and breast cancer risk. Methods: Studies were searched in the PubMed, Web of Science, Embase, Wanfang Med Online, and China National Knowledge Infrastructure databases until September 20, 2019 to identify all potential literature on this association. Fixed-effect or random-effect models were used to calculate odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs). Subgroup and sensitivity analyses and tests for publication bias were also performed. Results: Five eligible studies involving 2823 subjects (1410 patients and 1413 healthy controls) were included in the current meta-analysis. The pooled analysis indicated a positive correlation between the RAGE rs1800624 polymorphism and the risk of breast cancer in a homozygous genetic model (OR = 1.423, 95% CI = 1.043–1.941, P = .026). Ethnicity-based subgroup analysis demonstrated that RAGE rs1800624 polymorphism may increase the risk of breast cancer in the Asian population in homozygous model (OR = 1.661, 95% CI = 1.178–2.342, P = .004). Conclusion: The RAGE rs1800624 polymorphism may increase the risk of breast cancer in the homozygous genetic model, especially in Asian populations. Large-scale and well-designed studies are needed in different populations to further evaluate the role of the RAGE polymorphism in breast cancer.

show abstract

Polymorphisms of the promoter and exon 3 of the receptor for advanced glycation end products (RAGE) in Euro‐ and Afro‐Brazilians

Cited by 10 publications

References 44 publications

Association of RAGE gene Gly82Ser polymorphism with coronary artery disease and ischemic stroke

Association of RAGE gene Gly82Ser polymorphism with coronary artery disease and ischemic stroke

An Interactive Association of Advanced Glycation End-Product Receptor Gene Four Common Polymorphisms with Coronary Artery Disease in Northeastern Han Chinese

Receptor for advanced glycation end-product rs1800624 polymorphism contributes to increase breast cancer risk

Contact Info

Product

Resources

About